25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017

      research-article
      , MD 1 , , , MD, MPH 2 , , MD, MPH 3 , 4
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This cross-sectional analysis assesses the prevalence and number of alcohol- or benzodiazepine-involved opioid overdose deaths by opioid subtypes in the United States from 1999 to 2017.

          Key Points

          Question

          What is the prevalence of alcohol or benzodiazepine co-involvement in opioid overdose deaths among the opioid subtypes currently and over time?

          Findings

          This repeated cross-sectional analysis of deaths attributed to opioid overdose identified the co-involvement of alcohol or benzodiazepines as common and increasing, reaching 14.7% for alcohol and 21.0% for benzodiazepines in 2017. Significant correlations occurred between state-level binge drinking rates and alcohol co-involvement and between state-level benzodiazepine prescribing rates and benzodiazepine co-involvement in opioid overdose deaths.

          Meaning

          Prevalence of respiratory-depressing drugs in opioid overdose deaths is common and increasing and represents a potential target for policy and practice efforts to reduce opioid-related harms.

          Abstract

          Importance

          The use of benzodiazepines or alcohol together with opioids increases overdose risk, but characterization of co-involvement by predominant opioid subtype is incomplete to date. Understanding the use of respiratory depressants in opioid overdose deaths (OODs) is important for prevention efforts and policy making.

          Objective

          To assess the prevalence and number of alcohol- or benzodiazepine-involved OODs by opioid subtypes in the United States from 1999 to 2017.

          Design and Setting

          This repeated cross-sectional analysis used data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (WONDER) database of all opioid-involved poisoning deaths from January 1, 1999, to December 31, 2017, for the United States. State-level binge drinking prevalence rates for 2015 to 2017 were obtained from the Behavior Risk Factor Surveillance System of the Centers for Disease Control and Prevention, and benzodiazepine prescribing rates for 2012 (most recent available data) were obtained from IMS Health, a commercial database. Data were analyzed from July 10, 2018, to May 16, 2019.

          Main Outcomes and Measures

          Prevalence of alcohol or benzodiazepine co-involvement for all OODs and by opioid subtype, nationally and by state.

          Results

          From 1999 to 2017, 399 230 poisoning deaths involved opioids, of which 263 601 (66.0%) were male, and 204 560 (51.2%) were aged 35 to 54 years. Alcohol co-involvement for all opioid overdose deaths increased nonlinearly from 12.4% in 1999 to 14.7% in 2017. By opioid subtype, deaths involving heroin and synthetic opioids (eg, fentanyl; excluding methadone) had the highest alcohol co-involvement at 15.5% and 14.9%, respectively, in 2017. Benzodiazepine co-involvement in all OODs increased nonlinearly from 8.7% in 1999 to 21.0% in 2017. Benzodiazepines were present in 33.1% of prescription OODs and 17.1% of synthetic OODs in 2017. State-level rates of binge drinking were significantly correlated with alcohol co-involvement in all OODs ( r = 0.34; P = .02). State benzodiazepine prescribing rates were significantly correlated with benzodiazepine co-involvement in all OODs ( r = 0.57; P < .001).

          Conclusions and Relevance

          This study found that alcohol and benzodiazepine co-involvement in opioid-involved overdose deaths was common, varied by opioid subtype, and was associated with state-level binge drinking and benzodiazepine prescribing rates. These results may inform state policy initiatives in harm reduction and overdose prevention efforts.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Polydrug abuse: a review of opioid and benzodiazepine combination use.

          This paper reviews studies examining the pharmacological interactions and epidemiology of the combined use of opioids and benzodiazepines (BZDs). A search of English language publications from 1970 to 2012 was conducted using PubMed and PsycINFO(®). Our search found approximately 200 articles appropriate for inclusion in this paper. While numerous reports indicate that the co-abuse of opioids and BZDs is ubiquitous around the world, the reasons for the co-abuse of these medications are not entirely clear. Though the possibility remains that opioid abusers are using BZDs therapeutically to self-medicate anxiety, mania or insomnia, the data reviewed in this paper suggest that BZD use is primarily recreational. For example, co-users report seeking BZD prescriptions for the purpose of enhancing opioid intoxication or "high," and use doses that exceed the therapeutic range. Since there are few clinical studies investigating the pharmacological interaction and abuse liability of their combined use, this hypothesis has not been extensively evaluated in clinical settings. As such, our analysis encourages further systematic investigation of BZD abuse among opioid abusers. The co-abuse of BZDs and opioids is substantial and has negative consequences for general health, overdose lethality, and treatment outcome. Physicians should address this important and underappreciated problem with more cautious prescribing practices, and increased vigilance for abusive patterns of use.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis

            Objectives To identify trends in concurrent use of a benzodiazepine and an opioid and to identify the impact of these trends on admissions to hospital and emergency room visits for opioid overdose. Design Retrospective analysis of claims data, 2001-13. Setting Administrative health claims database. Participants 315 428 privately insured people aged 18-64 who were continuously enrolled in a health plan with medical and pharmacy benefits during the study period and who also filled at least one prescription for an opioid. Interventions Concurrent benzodiazepine/opioid use, defined as an overlap of at least one day in the time periods covered by prescriptions for each drug. Main outcome measures Annual percentage of opioid users with concurrent benzodiazepine use; annual incidence of visits to emergency room and inpatient admissions for opioid overdose. Results 9% of opioid users also used a benzodiazepine in 2001, increasing to 17% in 2013 (80% relative increase). This increase was driven mainly by increases among intermittent, as opposed to chronic, opioid users. Compared with opioid users who did not use benzodiazepines, concurrent use of both drugs was associated with an increased risk of an emergency room visit or inpatient admission for opioid overdose (adjusted odds ratio 2.14, 95% confidence interval 2.05 to 2.24; P<0.001) among all opioid users. The adjusted odds ratio for an emergency room visit or inpatient admission for opioid overdose was 1.42 (1.33 to 1.51; P<0.001) for intermittent opioid users and 1.81 (1.67 to 1.96; P<0.001) chronic opioid users. If this association is causal, elimination of concurrent benzodiazepine/opioid use could reduce the risk of emergency room visits related to opioid use and inpatient admissions for opioid overdose by an estimated 15% (95% confidence interval 14 to 16). Conclusions From 2001 to 2013, concurrent benzodiazepine/opioid use sharply increased in a large sample of privately insured patients in the US and significantly contributed to the overall population risk of opioid overdose.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016

              This study uses National Vital Statistics System data to describe trends in synthetic opioid involvement in drug overdose deaths in the United States from 2010 to 2016.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                9 April 2020
                April 2020
                9 April 2020
                : 3
                : 4
                : e202361
                Affiliations
                [1 ]Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts
                [2 ]Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts
                [3 ]Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts
                [4 ]Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts
                Author notes
                Article Information
                Accepted for Publication: February 13, 2020.
                Published: April 9, 2020. doi:10.1001/jamanetworkopen.2020.2361
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Tori ME et al. JAMA Network Open.
                Corresponding Author: Marco E. Tori, MD, Department of Medicine, Boston University School of Medicine, Boston Medical Center, 801 Massachusetts Ave, 2nd Floor, Boston, MA 02118 ( marco.tori@ 123456bmc.org ).
                Author Contributions: Dr Tori had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: All authors.
                Acquisition, analysis, or interpretation of data: Tori, Larochelle.
                Drafting of the manuscript: Tori, Naimi.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Tori.
                Administrative, technical, or material support: Naimi.
                Supervision: Larochelle, Naimi.
                Conflict of Interest Disclosures: Dr Larochelle reported research support paid to Boston Medical Center from OptumLabs outside the submitted work. No other disclosures were reported.
                Additional Contributions: Lucy Schulson, MD, MPH, Boston Medical Center General Internal Medicine, provided manuscript editing and feedback. She was not compensated for this contribution.
                Article
                zoi200121
                10.1001/jamanetworkopen.2020.2361
                7146101
                32271389
                ffd20400-0df0-46a6-8c96-ccca994ae0bb
                Copyright 2020 Tori ME et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 23 October 2019
                : 13 February 2020
                Categories
                Research
                Original Investigation
                Online Only
                Substance Use and Addiction

                Comments

                Comment on this article